Baseline characteristics

Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma · Source last updated 2016-08-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

1. counts

   1. group Id

      BG000

      value

      46

   units

   Participants

groups

1. description

   PHASE I: Patients receive flavopiridol IV over 4½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of flavopiridol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. PHASE II: Patients receive flavopiridol\* as in phase I at the MTD determined in phase I. alvocidib: Given IV

   id

   BG000

   title

   Treatment (Alvocidib)

measures

1. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            lower Limit

            34

            upper Limit

            84

            value

            66

   dispersion Type

   FULL_RANGE

   param Type

   MEDIAN

   title

   Age, Continuous

   unit Of Measure

   years

2. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            20

         title

         Female

      2. measurements

         1. group Id

            BG000

            value

            26

         title

         Male

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Sex: Female, Male

   unit Of Measure

   Participants

3. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            45

      title

      United States

   2. categories

      1. measurements

         1. group Id

            BG000

            value

            1

      title

      Canada

   param Type

   NUMBER

   title

   Region of Enrollment

   unit Of Measure

   patients

4. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            8

      title

      0 (Fully active)

   2. categories

      1. measurements

         1. group Id

            BG000

            value

            34

      title

      1 (Restricted in physically strenuous activity)

   3. categories

      1. measurements

         1. group Id

            BG000

            value

            4

      title

      2 (Ambulatory capable of all selfcare)

   param Type

   NUMBER

   title

   Eastern Cooperative Oncology Group (ECOG) Performance status

   unit Of Measure

   patients

5. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            15

      title

      Indolent B-cell

   2. categories

      1. measurements

         1. group Id

            BG000

            value

            17

      title

      intermediate grade B-NHL

   3. categories

      1. measurements

         1. group Id

            BG000

            value

            7

      title

      Mantle cell lymphoma

   4. categories

      1. measurements

         1. group Id

            BG000

            value

            7

      title

      T/NK cell NHL

   param Type

   NUMBER

   title

   Diagnosis

   unit Of Measure

   patients

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice